Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Stockholders DeficitTransBiotec Inc [Member]
Noncontrolling Interest [Member]
Balance, shares at Dec. 31, 2017 109,409,930 1,388,575
Balance, amount at Dec. 31, 2017 $ (2,964,137) $ 1,096 $ 14 $ 14,785,051 $ (17,703,171) $ (2,917,010) $ (47,127)
Common stock issued to settle accounts payable, shares   91,148          
Common stock issued to settle accounts payable, amount 428 $ 1   427   428  
Paid-in capital - relative fair value of stock warrants granted 10,958   10,958   10,958  
Paid-in capital - gain on related party debt conversion 7,776   7,776   7,776  
Net Income (Loss) $ (143,870) $ (143,049) $ (143,049) $ (821)
Balance, shares at Mar. 31, 2018 109,501,078 1,388,575
Balance, amount at Mar. 31, 2018 $ (3,088,845) $ 1,097 $ 14 $ 14,804,212 $ (17,846,220) $ (3,040,897) $ (47,948)
Paid-in capital - relative fair value of stock warrants granted 18,743   18,743   18,743  
Paid-in capital - gain on related party debt conversion 7,367   7,367   7,367  
Net Income (Loss) (151,614) $ (150,810) (150,810) $ (804)
Common stock issued for services, shares   6,000,000          
Common stock issued for services, amount 25,800 $ 61   25,739   25,800  
Common stock issued for compensation, shares   800,000          
Common stock issued for compensation, amount 8,000 $ 9   7,991   8,000  
Common stock issued due to options exercise, shares   450,000          
Common stock issued due to options exercise, amount 4,500 $ 5   4,495   4,500  
Paid-in capital - beneficial conversion feature $ 6,000   $ 6,000   $ 6,000  
Balance, shares at Jun. 30, 2018 116,751,078 1,388,575
Balance, amount at Jun. 30, 2018 $ (3,170,049) $ 1,172 $ 14 $ 14,874,547 $ (17,997,030) $ (3,121,297) $ (48,752)
Paid-in capital - gain on related party debt conversion 6,123   6,123   6,123  
Net Income (Loss) $ (133,611) $ (132,842) $ (132,842) $ (769)
Balance, shares at Sep. 30, 2018 116,751,078 1,388,575
Balance, amount at Sep. 30, 2018 $ (3,297,537) $ 1,172 $ 14 $ 14,880,670 $ (18,129,872) $ (3,248,016) $ (49,521)
Balance, shares at Dec. 31, 2018 116,751,078 1,388,575
Balance, amount at Dec. 31, 2018 $ (3,423,431) $ 1,172 $ 14 $ 14,887,804 $ (18,262,136) $ (3,373,146) $ (50,285)
Paid-in capital - relative fair value of stock warrants granted 22,665   22,665   22,665  
Paid-in capital - gain on related party debt conversion 8,113   8,113   8,113  
Net Income (Loss) (139,056) $ (138,289) (138,289) $ (767)
Common stock issued for cash, shares   35,454,547          
Common stock issued for cash, amount $ 39,000 $ 350   $ 38,650   $ 39,000  
Balance, shares at Mar. 31, 2019 152,205,625 1,388,575
Balance, amount at Mar. 31, 2019 $ (3,492,709) $ 1,522 $ 14 $ 14,957,232 $ (18,400,425) $ (3,441,657) $ (51,052)
Paid-in capital - relative fair value of stock warrants granted 12,365   12,365   12,365  
Paid-in capital - gain on related party debt conversion 7,409   7,409   7,409  
Net Income (Loss) $ (156,955) $ (156,137) $ (156,137) $ (818)
Balance, shares at Jun. 30, 2019 152,205,625 1,388,575
Balance, amount at Jun. 30, 2019 $ (3,629,890) $ 1,522 $ 14 $ 14,977,006 $ (18,556,562) $ (3,578,020) $ (51,870)
Paid-in capital - relative fair value of stock warrants granted 19,505   19,505   19,505  
Paid-in capital - gain on related party debt conversion 13,071   13,071   13,071  
Net Income (Loss) (216,106) $ (215,343) (215,343) $ (763)
Common stock issued for accrued executive compensation, shares   14,000,000          
Common stock issued for accrued executive compensation, amount 59,500 $ 140   59,360   59,500  
Common stock issued due to stock warrants exercise, shares   34,535,165          
Common stock issued due to stock warrants exercise, amount 146,774 $ 345   146,429   146,774  
Common stock issued upon conversion of convertible preferred stock to common stock, shares   13,885,750 (1,388,575)        
Common stock issued upon conversion of convertible preferred stock to common stock, amount (1,329,561) $ 139 $ (14) (1,329,686)   (1,329,561)  
Paid-in capital - gain on related party executive compensation conversion 535,500   535,500   535,500  
Paid-in capital - gain on related party preferred stock conversion $ 1,329,561   $ 1,329,561   $ 1,329,561  
Balance, shares at Sep. 30, 2019 214,626,540
Balance, amount at Sep. 30, 2019 $ (3,071,646) $ 2,146 $ 15,750,746 $ (18,771,905) $ (3,019,013) $ (52,633)